The Phase III FIND-CKD trial reported that finerenone significantly slowed kidney function decline and reduced cardiovascular risk in adults with non-diabetic chronic kidney disease. As a mineralocorticoid receptor antagonist with a long clinical track record in diabetic CKD, the data expand evidence into a broader CKD population and sharpen the competitive landscape for kidney-protective regimens. At the ERA Congress, additional renal-metabolic data highlighted FLOW, where once-weekly semaglutide improved quality-of-life outcomes and key clinical endpoints in adults with type 2 diabetes and chronic kidney disease. The combined dataset reinforces GLP-1 and kidney-protective class positioning as the industry’s center of gravity for CKD management. For biotech and pharma, the message is clear: renal endpoints are becoming increasingly multi-dimensional—function, cardiovascular outcomes, and patient-reported measures are all converging on the same development programs.